文献速递免疫规划卫生政策与健康促进

中东和非洲地区的疫苗筹资:2010年至2019年概览

Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019.
PubMed 文献 · Vaccine · 2022-08-25

该研究对69个中东和非洲国家2010至2019年的疫苗筹资数据进行了针对性文献综述和描述性分析。结果显示,96%的国家有疫苗接种支出数据,但预算数据有限且变异性大;人均接种支出中位数为0.57至1.02美元,高收入国家最高(中位数3.41美元),低收入国家为0.69美元。结论认为确保充足筹资对维持现有免疫规划并引入新疫苗十分重要。

要点

  • 96%的中东和非洲国家有疫苗接种支出数据,但预算数据有限且变异性大。
  • 人均接种支出中位数0.57至1.02美元,高收入国家最高(3.41美元),低收入国家0.69美元。
  • 低收入国家接种支出占GDP比例最高(0.10%),高收入国家最低(0.01%)。

核心结论

  • 中东和非洲地区的疫苗接种支出数据可用于详细分析,有助于了解该地区疫苗筹资特征。
  • 确保充足筹资对维持现有免疫规划并引入新疫苗十分重要。

研究设计与样本

  • 针对69个中东和非洲国家2010年至2019年数据进行的针对性文献综述及描述性分析。

主要发现

  • 96%的国家有疫苗接种支出数据,但预算数据有限且变异性高。
  • 人均接种支出中位数为0.57至1.02美元。
  • 高收入国家人均接种支出中位数3.41美元,高于低收入国家的0.69美元。
  • 疫苗接种项目100%由政府资助的国家人均接种支出最高(0.87美元),政府支付>0%至<50%接种支出的国家为0.74美元。
  • 低收入国家接种支出占GDP比例最高(0.10%),高收入国家最低(0.01%);占医疗卫生支出比例低收入国家最高(1.76%),高收入国家最低(0.33%)。

关键数值与推荐

  • 27%的国家人均支出中位数呈现统计学显著趋势。
  • 研究期间平均引入4.4种疫苗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination is a cost-effective disease prevention measure. Sustainable financing is critical to successful implementation of vaccination programs. Countries in the Middle East and Africa (MEA) have vaccination programs that remain highly vulnerable to budget limitations. OBJECTIVES: The objectives of this study were to understand the current vaccine financing landscape in MEA; to assess the availability and variability of data on vaccination budgets, expenditure and schedules including introductions of new vaccines; and to identify and describe key trends. METHOD: A targeted literature review was conducted for 69 MEA countries for data between 2010 and 2019. Descriptive analysis of the collected data was conducted. RESULTS: Data on vaccination expenditure were available for 96% of the countries. However, data on vaccination budget were limited, and the variability was high. The median vaccination expenditure per capita was between US$0.57 and US$1.02. High-income countries spent the most on vaccination per capita (median US$3.41) compared to low-income countries (median US$0.69). The highest vaccination expenditure per capita was in countries that receive 100% government funding of vaccination programs (US$0.87) compared to those where government pays for > 0% to < 50% of vaccination expenditure (US$0.74). Vaccination expenditure as a proportion of gross domestic product was the highest (0.10%) in low-income countries and the lowest in high-income countries (0.01%). Vaccination expenditure as proportion of healthcare expenditure was the highest (1.76%) in low-income countries and the lowest in high-income countries (0.33%). Statistically significant trends in median expenditure per capita were identified for 27% of the countries. During this period, an average of 4.4 vaccines were introduced. CONCLUSION: Data on vaccination expenditure in MEA was available for detailed analysis, and it was useful to understand the characteristics of vaccination funding in the region. It is important to secure adequate financing to sustain current vaccination programs and to introduce new vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Catharina de Beer J, Goto D, Miller-Janson H, et al. Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019. Vaccine. 2022. PMID: 36030126. doi:10.1016/j.vaccine.2022.06.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。